The potential of enzastaurin to enhance platelet aggregation and growth factor secretion: implications for cancer cell survival.

about

Platelet releasates promote the proliferation of hepatocellular carcinoma cells by suppressing the expression of KLF6 Antiplatelet agents for cancer treatment: a real perspective or just an echo from the past?

P2860

Q33822598-1CB305CF-2B50-413A-9F7B-3E30606DDCCD Q41420993-A246850F-5765-45D6-AF72-247D4D0839C0

P2860

The potential of enzastaurin to enhance platelet aggregation and growth factor secretion: implications for cancer cell survival.

Item

http://www.wikidata.org/entity/Q38873064

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

The potential of enzastaurin t ...... ions for cancer cell survival.

@en

type

Item

label

The potential of enzastaurin t ...... ions for cancer cell survival.

@en

prefLabel

The potential of enzastaurin t ...... ions for cancer cell survival.

@en

P1476

The potential of enzastaurin t ...... ions for cancer cell survival.

@en

P2093

G Lesyk

http://www.w3.org/2001/XMLSchema#string

P Jurasz

http://www.w3.org/2001/XMLSchema#string

P P Ruvolo

http://www.w3.org/2001/XMLSchema#string

T Fong

http://www.w3.org/2001/XMLSchema#string

P2860

Differential platelet levels affect response to taxane-based therapy in ovarian cancer.

Increased efficacy of breast cancer chemotherapy in thrombocytopenic mice

Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials.

Estimates of benefits and harms of prophylactic use of aspirin in the general population.

Venous thromboembolism is a relevant and underestimated adverse event in cancer patients treated in phase I studies.

Identification of luminal breast cancers that establish a tumor-supportive macroenvironment defined by proangiogenic platelets and bone marrow-derived cells.

Platelets increase survival of adenocarcinoma cells challenged with anticancer drugs: mechanisms and implications for chemoresistance.

Phase 2 randomized study of enzastaurin (LY317615) for lung cancer prevention in former smokers.

Enzastaurin hydrochloride for lymphoma: reassessing the results of clinical trials in light of recent advances in the biology of B-cell malignancies.

Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials.

P304

1514-1520

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/JTH.13010

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-06-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25990653

http://www.w3.org/2001/XMLSchema#string

The potential of enzastaurin to enhance platelet aggregation and growth factor secretion: implications for cancer cell survival.

about

P2860

P2860

The potential of enzastaurin to enhance platelet aggregation and growth factor secretion: implications for cancer cell survival.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698